Managing Erythrocytosis on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

By
Published Updated Last reviewed
Medication safety clinical consultation image for Managing Erythrocytosis on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

Managing Erythrocytosis on AndroGel (testosterone topical): The HealthRX Step-by-Step Protocol

At a glance

  • Incidence: Hematocrit >54% occurs in approximately 3 to 18% of men on topical testosterone across controlled trials; injectable formulations carry higher rates (up to 40 to 50% in some cohorts), making gel a lower-risk but not zero-risk delivery route. The AndroGel 1% prescribing information lists erythrocytosis as a known adverse effect requiring monitoring.
  • Typical timeline: Hematocrit rises begin within 3 months of starting therapy; most clinically significant elevations appear between months 3 and 12 of use, per Bhasin et al., NEJM 2010.
  • First-line management: Dose reduction to the next lower labeled step (e.g., 5 g/day to 2.5 g/day) plus increased oral fluid intake.
  • Escalation trigger: Hematocrit ≥54% confirmed on repeat draw, or any hematocrit paired with symptoms of hyperviscosity (headache, visual changes, chest pain, dyspnea).
  • Discontinuation threshold: Persistent hematocrit ≥54% despite dose reduction and phlebotomy, or any thrombotic event.

Why AndroGel Causes Erythrocytosis

Testosterone stimulates erythropoiesis through two converging pathways. First, it directly stimulates the kidneys to increase erythropoietin (EPO) synthesis, which drives red cell production in the bone marrow. Second, testosterone suppresses hepcidin, the hepatic hormone that limits iron availability for erythropoiesis, effectively releasing more substrate for red cell production. Both pathways are active regardless of delivery route.

AndroGel produces a steadier, lower peak serum testosterone level compared with intramuscular injections, which is why erythrocytosis rates are lower with gel formulations. Grimes et al. (Urology, 2021) confirmed in a large retrospective cohort that transdermal testosterone was significantly less likely to cause hematocrit elevation above 50% than injectable testosterone, though the risk remained clinically meaningful. A 2013 meta-analysis in JCEM by Calof et al. found that across formulations, erythrocytosis (hematocrit >50%) had an odds ratio of 3.69 versus placebo in testosterone trials, underscoring that even gel carries real risk.

The clinical danger is hyperviscosity. As hematocrit climbs past 52 to 54%, whole blood viscosity rises non-linearly, increasing the risk of venous thromboembolism and arterial thrombotic events. The AUA Guidelines on Testosterone Deficiency (2022) specifically flag hematocrit >54% as an actionable threshold for this reason.

Step 1: Baseline Assessment Before Starting AndroGel

The protocol begins before the first dose.

Obtain a complete blood count (CBC) with differential at baseline. Record hematocrit, hemoglobin, and red cell indices. If baseline hematocrit is already ≥50%, investigate the cause before prescribing. Conditions that raise baseline hematocrit, including obstructive sleep apnea, chronic hypoxia, smoking, and polycythemia vera, substantially increase the risk that AndroGel will push values into dangerous territory.

The Endocrine Society Clinical Practice Guideline (2018) recommends screening for untreated sleep apnea before initiating TRT specifically because it compounds testosterone-driven erythrocytosis. Patients with a baseline hematocrit of 48 to 50% should be counseled explicitly about this risk and monitored more frequently.

Classify cardiovascular risk at baseline. Patients with prior VTE, known thrombophilia, or polycythemia vera are listed as contraindications or high-risk populations in the FDA-approved prescribing information for AndroGel 1.62%. Document this assessment in the chart before the first prescription is written.

Step 2: Monitoring Schedule

Monitoring frequency determines how quickly the protocol can intervene.

  • Month 3: First CBC after starting AndroGel. This is the window when most early hematocrit rises appear.
  • Month 6: Repeat CBC. If hematocrit was stable at month 3, the rate of rise is slow; if it climbed >2 percentage points, accelerate monitoring.
  • Month 12: Annual CBC thereafter for stable patients.
  • Accelerated schedule: Any patient whose hematocrit exceeds 50% on any draw moves to every-3-month monitoring until values are stable below that threshold for two consecutive readings.

The AUA 2022 Testosterone Deficiency Guideline and the Endocrine Society both recommend CBC at 3 months, 6 months, and annually, with tighter intervals when values trend upward. Do not rely on symptoms alone. Most patients with hematocrit in the 52 to 54% range are asymptomatic. The risk is silent until a thrombotic event occurs.

Step 3: Interpreting the Hematocrit Result

Not every elevated hematocrit reading requires immediate action. The protocol distinguishes four zones:

Zone A (Hematocrit <50%): Continue current dose. No action required beyond scheduled monitoring.

Zone B (Hematocrit 50 to 53%): Investigate contributory factors. Ask about new snoring or witnessed apneas (sleep apnea), smoking, COPD exacerbations, and dehydration. Order a repeat CBC in 4 weeks to confirm the value is real and not a concentration artifact. If the repeat confirms elevation in this range without a reversible secondary cause, proceed to dose reduction (Step 4).

Zone C (Hematocrit 54 to 55%): Confirm the value with a repeat draw within 2 weeks. Do not wait for the next scheduled visit. Once confirmed, proceed immediately to dose reduction and evaluate for therapeutic phlebotomy in parallel. The American Urological Association's erythrocytosis guidance treats 54% as the ceiling for conservative management.

Zone D (Hematocrit >55%, or any value with hyperviscosity symptoms): Stop AndroGel immediately. Assess for thrombotic events. Refer urgently to hematology. Do not restart without specialist input. Symptoms warranting urgent evaluation include new-onset headache, visual blurring, plethora, chest pain, unilateral limb swelling, or confusion.

Step 4: First-Line Intervention, Dose Reduction

When hematocrit enters Zone B or Zone C, the first move is reducing the AndroGel dose.

AndroGel 1.62% is labeled at 40.5 mg/day (starting dose), 20.25 mg/day, and 81 mg/day. AndroGel 1% is available at 5 g/day and 2.5 g/day. Step down to the next lower dose. Recheck hematocrit in 6 to 8 weeks.

What success looks like here: Hematocrit falls back below 52% within 8 to 12 weeks of dose reduction. Serum testosterone should be remeasured at the same visit to confirm the patient remains within the therapeutic range. Bhasin et al. (NEJM 2010) demonstrated that erythrocytosis in TRT trials is dose-dependent, supporting the rationale that reducing exposure will reduce the hematocrit signal.

What failure looks like here: Hematocrit does not fall below 54% after 8 weeks on the reduced dose, or falls initially then rebounds. If this occurs, move to Step 5.

Adjunct: Hydration. Encourage the patient to increase water intake to at least 2, 2.5 liters per day. Relative dehydration can falsely concentrate hematocrit values and amplify a borderline result into an actionable one. This is not a standalone treatment, but it removes a confounding variable and may modestly improve true hematocrit in Zone B cases.

Step 5: Therapeutic Phlebotomy

When dose reduction alone does not bring hematocrit below 54% within 8 to 12 weeks, add therapeutic phlebotomy.

Standard approach: Remove 450 to 500 mL of whole blood, matching blood bank donation protocols. This acutely reduces hematocrit by approximately 3 percentage points in most adult men. Recheck CBC in 4 to 6 weeks.

Frequency: Phlebotomy can be repeated every 8 to 12 weeks as needed. The British Society for Haematology guidelines on polycythemia vera use hematocrit <45% (male) as their target, a more aggressive target than the 54% threshold used in TRT management. For AndroGel-related erythrocytosis, the practical target is hematocrit below 52% sustained between draws.

Iron monitoring: Repeated phlebotomy depletes iron stores. Check ferritin and serum iron at baseline before the first phlebotomy and after every second session. Bachman et al. (J Clin Endocrinol Metab, 2014) noted that iron-restricted erythropoiesis from phlebotomy can actually prevent further hematocrit rises in men on TRT even when the testosterone dose remains constant. This is not a bug; it is a mechanism you can use. However, symptomatic iron deficiency (fatigue, pallor, palpitations) requires reassessment of the phlebotomy schedule.

Who should perform phlebotomy: A hematologist or a blood center operating under a physician order. Primary care physicians can place the order; the procedure itself requires trained staff and appropriate monitoring.

What success looks like here: Hematocrit falls to <52% and stays there for two consecutive draws 8 weeks apart, without requiring phlebotomy more frequently than every 12 weeks.

What failure looks like here: Hematocrit rebounds to ≥54% within 6 weeks of each phlebotomy session, indicating the production rate on current AndroGel exposure exceeds what phlebotomy can safely offset. Proceed to Step 6.

Step 6: Discontinuation or Formulation Switch

If hematocrit remains ≥54% despite both dose reduction and phlebotomy at adequate intervals, discontinuation is the appropriate next step. The FDA prescribing label for AndroGel lists hematocrit elevation as a reason to withhold therapy until values normalize.

Discontinuation timeline: After stopping AndroGel, hematocrit typically returns to baseline within 3 to 4 months. Recheck CBC at weeks 6 and 12 post-discontinuation to confirm the downward trend.

Formulation switch consideration: If the patient's hypogonadism management goals still require testosterone, discuss the risk-benefit profile with the patient and an endocrinologist or urologist before trialing a different agent. Lower-dose or intranasal formulations (such as Natesto) produce lower and more transient serum testosterone peaks and may carry lower erythrocytosis risk, though comparative erythrocytosis data between gel and intranasal formulations remain limited. Any switch requires restarting CBC monitoring from baseline on the new formulation.

Absolute discontinuation triggers (no restart without specialist input):

  • Any confirmed VTE or arterial thrombotic event during AndroGel use
  • Hematocrit >58% on any single draw
  • Hyperviscosity symptoms at any hematocrit level

Communicating This Protocol to the Patient

Patients on AndroGel need three things explained clearly at initiation: what erythrocytosis is, why blood draws are not optional, and what symptoms should prompt same-day contact. Patient-facing FDA guidance on testosterone products specifically notes cardiovascular and hematologic risks as reasons for ongoing monitoring.

Frame blood counts as a safety check, not an inconvenience. A patient who understands that a hematocrit of 56% without symptoms can still precede a stroke is more likely to keep their monitoring appointments than one told simply to "watch out for dizziness."

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. AbbVie Inc. AndroGel 1% (testosterone gel) Prescribing Information. U.S. FDA. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s026lbl.pdf

  2. AbbVie Inc. AndroGel 1.62% (testosterone gel) Prescribing Information. U.S. FDA. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202763lbl.pdf

  3. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536, 2559. https://www.nejm.org/doi/full/10.1056/NEJMoa1001505

  4. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451, 1457. https://pubmed.ncbi.nlm.nih.gov/15941843/

  5. Grimes JM, Perez D, Waller J, et al. Polycythemia risk with testosterone therapy by injection versus transdermal delivery. Urology. 2021;157:146, 152. https://pubmed.ncbi.nlm.nih.gov/33581908/

  6. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietic pathway. J Gerontol A Biol Sci Med Sci. 2014;69(6):725, 735. https://pubmed.ncbi.nlm.nih.gov/24423359/

  7. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2022;208(2):423, 432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline

  8. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715, 1744. https://academic.oup.com/jcem/article/103/5/1715/4939465

  9. McMullin MF, Mead AJ, Ali S, et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology guideline. Br J Haematol. 2019;184(2):161, 175. https://onlinelibrary.wiley.com/doi/10.1111/bjh.15648

  10. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914, 919. https://pubmed.ncbi.nlm.nih.gov/18434255/

  11. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging. 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due